Berkshire’s Taylor Morrison (TMHC) acquisition clears key HSR antitrust step
Berkshire Hathaway's acquisition of homebuilder Taylor Morrison (TMHC) has cleared the Hart-Scott-Rodino antitrust waiting period, removing a key regulatory hurdle toward deal close. With the antitrust step behind it, the setup now hinges on deal spread compression and whether any remaining closing conditions narrow the gap to the announced price.
What happened
Berkshire Hathaway's acquisition of homebuilder Taylor Morrison (TMHC) has cleared the Hart-Scott-Rodino antitrust waiting period, removing a key regulatory hurdle toward deal close.
The read · Jul 7
TMHC's HSR clearance removes the main regulatory block on the Berkshire deal — the question is how much spread remains and whether any closing conditions could still derail the acquisition.
Wrong if
A material adverse change claim by Berkshire (extremely rare but possible in a severe housing downturn), unexpected shareholder vote failure, or revelation of undisclosed deal conditions could widen the spread or blow up the arb entirely.
CoverageSource: Stock Titan · Published here TUE, JUL 7 · 6:39 AM ET · the only report in this recordHow this is decided →
The chart · TMHCTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Taylor Morrison Home Corp (TMHC) confirmed that its pending acquisition by a Berkshire Hathaway entity has cleared the HSR antitrust review period, meaning the DOJ/FTC did not move to block the deal during the statutory window. This is a standard but critical milestone in M&A timelines — HSR clearance typically signals the deal is on track and removes the largest regulatory overhang for most domestic acquisitions.
TMHC operates as one of the top-ten U.S. homebuilders with roughly $8.1B in annual revenue, 23% gross margins, and $7.77 in diluted EPS. Berkshire's interest in the homebuilder aligns with its existing exposure to housing-adjacent businesses and its track record of acquiring steady cash-flow businesses at reasonable valuations.
The trade setup here is a classic merger-arb: if TMHC shares are trading at a discount to the announced deal price, the spread should compress now that the biggest regulatory risk is resolved. The key remaining variables are the final deal price, any shareholder vote, and financing conditions — none of which appear threatened by this development.
The bear case centers on macro housing risk: a sharp deterioration in U.S. housing demand or a Berkshire withdrawal for material adverse change (MAC) could unwind the deal, though MAC clauses are notoriously hard to invoke. With HSR cleared, the probability-weighted deal price has moved higher, and any remaining spread is now primarily timing risk rather than regulatory risk.
The read, in fullWhy it matters
HSR clearance is the most material regulatory hurdle in most domestic M&A — with it cleared, the remaining deal spread on TMHC is now primarily a timing and financing risk premium rather than a binary antitrust risk. Berkshire's balance sheet eliminates financing risk, tightening the arb further. TMHC's $8.1B revenue base and positive EPS ($7.77 diluted) support a rational strategic rationale for the acquirer.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUL 7 on
Next · what would move this
4-8 weeks into deal close. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD-0.8%
JUL 7 · first close after publicationJUL 23
Price context does not establish that the story caused the move.
▲ The case it holds
With HSR cleared and Berkshire's nearly unlimited financing capacity, the remaining deal spread on TMHC represents largely timing risk, and spread compression toward the announced deal price is the high-probability path given TMHC's solid $7.77 EPS and $8.1B revenue base supporting deal rationale.
▼ The case it breaks
A sudden deterioration in U.S. housing fundamentals could give Berkshire grounds to attempt a MAC invocation or renegotiation, and TMHC's revenue already showed a modest -0.6% YoY decline, signaling potential vulnerability to a softening market that could complicate the close.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →